Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
Editorial Group: Cochrane Movement Disorders Group
Published Online: 7 OCT 2009
Assessed as up-to-date: 19 FEB 2009
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD006661. DOI: 10.1002/14651858.CD006661.pub2.
- Publication Status: New
- Published Online: 7 OCT 2009
This article has been cited by:
- 1Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial, The Lancet, 2014, 384, 9949, 1196,
- 2Association of adverse effects with monoamine oxidase type B inhibitor and catechol-o-methyl transferase inhibitor combination therapy in Parkinson’s disease patients, Advances in Parkinson's Disease, 2012, 01, 01, 5, , , ,